Parasite Viability as a Measure of <i>In Vivo</i> Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
Georges F. R. Radohery, Annabelle Walz, Christin Gumpp, Mohammed H. Cherkaoui‐Rbati, Nathalie Gobeau, Jeremy Gower, Miles P. Davenport, Matthias Rottmann, James McCarthy, Jörg J. Möhrle, Maria Rebelo, Claudia Demarta‐Gatsi, David S. Khoury
Abstract
recrudescence of infection. Finally, using pharmacometrics modeling, we show that the apparent differences in the antimalarial activity of artesunate in mice and humans are partly explained by differences in host removal of dead parasites in the two hosts. However, these differences, along with different pharmacokinetic profiles, do not fully account for the differences in activity. (This study has been registered with the Australian New Zealand Clinical Trials Registry under identifier ACTRN12617001394336.).